[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517545":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":24,"studyPopulation":25,"armGroups":20,"interventions":26,"overallOfficials":20,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":20,"id":55,"slug":20,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":20,"maxAge":20,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":20,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Sichuan Cancer Hospital and Research Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":20},[9,13],{"measure":10,"description":11,"timeFrame":12},"Progress Freesurvival (PFS)","The time from the start of treatment until the patient progresses further or dies.","Average six months after study completion.",{"measure":14,"description":15,"timeFrame":12},"Overall Survival (OS)","Measure the time from the start of treatment to the time of death.",[17],{"measure":18,"description":19,"timeFrame":12},"Occurrence of adverse reactions","All adverse events were recorded.",null,{"allocation":20,"interventionModel":20,"interventionModelDescription":20,"primaryPurpose":20,"observationalModel":22,"timePerspective":23,"maskingInfo":20},"COHORT","PROSPECTIVE","1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer);\n2. To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures;\n3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed;\n4. To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).","Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital",[27],{"type":6,"name":28,"description":28,"armGroupLabels":20,"otherNames":20},"No intervention",[30],{"name":31,"role":32,"phone":33,"phoneExt":20,"email":34},"Dengfeng Wang, Learned scholar","CONTACT","15982222707","wonderful_96@163.com",[36],{"facility":37,"status":38,"city":39,"state":20,"zip":20,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Sichuan Cancer Hospital","RECRUITING","Chengdu","China","CN",{"type":43,"coordinates":44},"Point",[45,46],104.06667,30.66667,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":33,"phoneExt":20,"email":34},"Wang Dengfeng, Doctor",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Dengfeng Wang","Deputy chief","100517545",false,"NCT06018935","A Cohort Establishment Study of Total Management of Ovarian Cancer","A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)","Inclusion Criteria:\n\n1. Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;\n2. Can cooperate with later follow-up.\n\nExclusion Criteria:\n\n1. Patients with other malignant tumors or previous history of other malignant tumors;\n2. Have cognitive impairment.",true,"FEMALE",{"count":64,"type":65},500,"ESTIMATED","OBSERVATIONAL","A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).",[69,70],"Tumor of Female Reproductive System","Ovarian Cancer",[72,73,74],"Ovarian cancer","Cohort study","Whole-process management","2024-06-17",{"date":77,"type":78},"2024-06-20","ACTUAL",{"date":75,"type":78},{"date":81,"type":65},"2025-09-01",{"name":5,"class":6},1]